In order to achieve greater patient participation, the FAMHP has decided to extend its survey on the use of benzodiazepines and similar in the context of sleep disorders in Belgium by two months. The survey will therefore be accessible until 19 May 2020 inclusive.
Why is it important to participate in the survey?
In Belgium, the use of benzodiazepines and similar in the context of sleep disorders is fairly high.
The main objective of the survey is to obtain data on the use of these soporifics by Belgian patients and their dependency on these medicinal products. The results will help the FAMHP to take more targeted measures to promote the rational use of these products.
Since participation in this survey is voluntary, it is important to have enough responses to obtain meaningful results.
Encourage your patients to participate in the survey
Pharmacists are the best-placed people to encourage patients to participate in this survey. With the support of the APB, the FAMHP has sent out four pages of labels to dispensing pharmacists, with the News Briefs, to stick onto the boxes of the medicinal products that they issue to the patients concerned by the survey. This label will include the address of the FAMHP website. The survey will be accessible via the landing page of the FAMHP website until 19 May 2020 inclusive.
The FAMHP also encourages other healthcare professionals to mention the survey to the patients concerned.
To reiterate, the survey is intended for patients:
- who have recently used a soporific covered by the survey
- aged 18 and over,
- who reside in Belgium,
- who are not being treated in a hospital, a nursing home or a care home.
The survey is anonymous. It should take the patient between 5 and 10 minutes to complete it. In the event of difficulties, patients may enlist the help of a friend or family member, or their pharmacist, to complete it.
No labels? Questions concerning the survey? Contact ADR@afmps.be.
The FAMHP thanks patients and healthcare professionals in advance for their collaboration.